Published in Biomaterials on February 21, 2012
Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012) 2.65
Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine (2014) 1.22
Microneedles for intradermal and transdermal drug delivery. Eur J Pharm Sci (2013) 1.18
Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release (2012) 0.90
Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol (2013) 0.89
Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications. Acta Biomater (2013) 0.84
The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother (2016) 0.83
A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment. PLoS One (2013) 0.82
Microneedle patches for vaccination in developing countries. J Control Release (2015) 0.79
Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles. PLoS One (2015) 0.77
Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin Drug Deliv (2014) 0.77
Controlled Drug Delivery Using Microdevices. Curr Pharm Biotechnol (2016) 0.77
The osmotic stress response of split influenza vaccine particles in an acidic environment. Arch Pharm Res (2013) 0.75
Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection. PLoS One (2017) 0.75
Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics (2015) 0.75
Universal and reusable virus deactivation system for respiratory protection. Sci Rep (2017) 0.75
Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches. Pharm Res (2015) 0.75
Anhydrobiosis. Annu Rev Physiol (1992) 5.37
Dose sparing with intradermal injection of influenza vaccine. N Engl J Med (2004) 5.14
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2004) 5.00
Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci (1997) 2.86
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Coated microneedles for transdermal delivery. J Control Release (2006) 2.66
Microneedle-based vaccines. Curr Top Microbiol Immunol (2009) 2.17
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine (2007) 1.89
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release (2011) 1.77
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release (2009) 1.71
Coating formulations for microneedles. Pharm Res (2007) 1.63
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine (2009) 1.55
Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med (2010) 1.46
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res (2010) 1.21
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine (2007) 1.19
The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm (1999) 1.11
Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res (2010) 1.03
Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol (2012) 1.02
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One (2010) 1.02
Characterization of three highly purified influenza virus strains by electron microscopy. J Gen Virol (1984) 1.02
Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis (2011) 1.01
Bevel-down superior to bevel-up in intradermal skin testing. Ann Allergy Asthma Immunol (1997) 0.99
Bacillus Calmette-Guérin vaccination using a microneedle patch. Vaccine (2011) 0.98
Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J Pharm Sci (2004) 0.96
Parathyroid hormone PTH(1-34) formulation that enables uniform coating on a novel transdermal microprojection delivery system. Pharm Res (2009) 0.92
Dehydration and crystallization of trehalose and sucrose glasses containing carbonmonoxy-myoglobin. Biophys J (1999) 0.91
Protein inactivation in amorphous sucrose and trehalose matrices: effects of phase separation and crystallization. Biochim Biophys Acta (1998) 0.90
Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system. Pharm Res (2009) 0.89
Crystal structure of an anhydrous form of trehalose: structure of water channels of trehalose polymorphism. J Phys Chem B (2008) 0.86
Some physicochemical properties of glassy indomethacin. Chem Pharm Bull (Tokyo) (1986) 0.85
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci U S A (2003) 2.82
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Coated microneedles for transdermal delivery. J Control Release (2006) 2.66
Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012) 2.65
Effect of microneedle design on pain in human volunteers. Clin J Pain (2008) 2.48
Dissolving microneedles for transdermal drug delivery. Biomaterials (2008) 2.47
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release (2005) 2.19
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Transdermal delivery of insulin using microneedles in vivo. Pharm Res (2004) 2.07
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Mechanism of intracellular delivery by acoustic cavitation. Ultrasound Med Biol (2006) 2.02
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech (2004) 1.91
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Micro-scale devices for transdermal drug delivery. Int J Pharm (2008) 1.81
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A (2008) 1.77
Polymer microneedles for controlled-release drug delivery. Pharm Res (2006) 1.72
Coating formulations for microneedles. Pharm Res (2007) 1.63
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Precise microinjection into skin using hollow microneedles. J Invest Dermatol (2006) 1.51
Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater (2008) 1.49
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Mechanism of fluid infusion during microneedle insertion and retraction. J Control Release (2006) 1.46
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Measurement and correlation of acoustic cavitation with cellular bioeffects. Ultrasound Med Biol (2006) 1.43
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Physical parameters influencing optimization of ultrasound-mediated DNA transfection. Ultrasound Med Biol (2004) 1.37
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol (2010) 1.36
Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng (2005) 1.35
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury. J Neurol Sci (2009) 1.31
Tapered conical polymer microneedles fabricated using an integrated lens technique for transdermal drug delivery. IEEE Trans Biomed Eng (2007) 1.30
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release (2011) 1.21
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res (2010) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20